Sermorelin Pre-Cycle vs Post-Cycle Research: What's the Difference?

The difference is in the research question, not the compound. "Pre-cycle" framing describes investigations that characterize the growth hormone axis at baseline — before any other variable is introduced into an experimental model. "Post-cycle" framing describes investigations that look at the same axis after a suppressive or competing variable has been withdrawn. Sermorelin appears in both conversations because it is a synthetic analog of growth hormone-releasing hormone, and the questions people ask about GHRH signaling naturally split along that before/after line. The vial is identical. The study design, the endpoints, and the documentation a serious buyer expects from a supplier are not.

One scope note before anything else: Real Peptides supplies research-use-only compounds to businesses. Nothing here is a protocol, a timing schedule, a preparation instruction, or a suggestion about human use. This article is written for the person deciding what to stock and which supplier to trust — not for anyone designing an intervention.

The molecule stays the same; the timeline around it changes

Sermorelin is a synthetic fragment corresponding to the first 29 amino acids of growth hormone-releasing hormone, presented as an amidated peptide. Research on it centers on the GHRH receptor found on pituitary somatotrophs. Because it acts upstream — prompting the pituitary rather than substituting for its output — studies involving sermorelin tend to be interested in the shape of endogenous secretion rather than in raw circulating concentration. Research suggests that secretagogue-style approaches remain subject to the body's own regulatory brakes, including somatostatin tone and downstream feedback, which is precisely why the compound shows up in work concerned with pulsatility and feedback integrity.

That upstream position is what makes the before/after distinction meaningful. If a model's axis has not been disturbed, the questions available are baseline questions: what does receptor responsiveness look like, how does response vary across a population, how reproducible is the signal across repeated measurements. If the axis has been disturbed by some prior variable and that variable has been removed, the questions become recovery questions: how quickly does endogenous signaling reassert itself, does the response curve return to its prior shape, and what confounds the measurement during that window.

It is worth being honest about the vocabulary. "Pre-cycle" and "post-cycle" are colloquial terms that migrated into peptide discussion from performance communities; they are not formal pharmacological categories. A buyer will hear them constantly from customers and almost never see them in a paper. Understanding what people mean by them — a baseline-phase question versus a recovery-phase question — is what lets you have a competent conversation without drifting into territory that belongs to a licensed professional.

Side by side: two framings, one compound

The table below compares the two framings on the dimensions that actually matter to someone sourcing material rather than running the work.

Read that last row carefully, because it is the one with commercial consequences. The two framings do not generate the same purchasing behavior even when they generate the same SKU.

What the distinction actually changes on the demand side

A buyer who understands the split stocks differently. Baseline-oriented interest tends to be methodical: the customer is planning ahead, wants documentation before purchase, and reorders on a schedule they can describe to you. Recovery-oriented interest tends to arrive in bursts, is more time-pressured, and is far less tolerant of a backorder — the window the customer cares about has already started.

This matters because your supplier's fulfillment reliability is not a uniform requirement across your catalog. A compound that sells into episodic, time-sensitive demand punishes stockouts much harder than one that sells into planned demand. If your supplier's lead times are opaque, you absorb that risk on the customer-facing side.

The second demand-side effect is adjacency. GHRH-analog interest rarely sits alone. Customers researching this corner of the growth hormone axis usually look at neighboring secretagogue chemistry at the same time, which means your catalog gets judged as a category rather than as a list of individual items. A shelf that carries one GHRH analog and nothing adjacent reads as incomplete to a knowledgeable buyer. Margins across these categories vary widely with volume, compound, and how you position your business, so treat category completeness as a credibility question first and a margin question second.

Purity is an experimental variable, not a marketing line

Here is the part most wholesale conversations skip. In any research framing that compares a before-state to an after-state, the material itself has to be the constant. If lot A and lot B differ in peptide content, impurity profile, or identity confirmation, every difference the researcher observes is contaminated by a supply variable they did not intend to introduce. That is a bigger problem in recovery-phase work, where the signal being tracked is already moving, than in clean baseline work — but it degrades both.

So the purity number on a certificate is not a bragging metric. It is a statement about how much of the vial is the thing it says it is, and how much is something else. Related-substance impurities in synthetic peptides can include truncated sequences, deletion sequences, and oxidation products — species close enough to the target to be invisible without proper analysis and different enough to matter.

When you evaluate any supplier, ask these questions in this order:

• Is the certificate batch-specific, or a reference document? A COA that carries no lot number, no test date, and no analyst attribution tells you what the supplier hopes is true about the compound in general, not what is true about the vial in the box.
• Is purity reported by HPLC with a visible chromatogram? A bare percentage with no trace behind it is an assertion. The chromatogram is the evidence.
• Is identity confirmed separately from purity? Purity says the peak is clean. Identity — typically by mass spectrometry — says the clean peak is the right molecule. They are different questions and a serious panel answers both.
• Does the panel cover the non-purity attributes? Sterility, bacterial endotoxin, bioburden, residual solvents, moisture, and appearance are each their own failure mode, and none of them shows up on an HPLC trace.
• Can you retrieve the COA yourself, by lot, without asking? This is the single fastest tell. A supplier confident in its results publishes them. A supplier that sends documentation only on request — or treats testing as a paid add-on — has told you something about how often it tests.

That last practice is more common in this industry than it should be. Hidden pricing behind a sales call, testing offered as an upsell, and "third-party tested" claims with no retrievable document are all patterns worth treating as disqualifying.

Supplier questions worth settling before you commit

Beyond the lab panel, the mechanics of a wholesale relationship deserve the same scrutiny. Pricing structure should be legible before you apply, not revealed after a qualification call — you should be able to see how tiers step down as volume increases and where the thresholds sit. Minimum order quantities should be stated plainly rather than negotiated case by case, because an MOQ you cannot see is an MOQ that can move.

Ask how lot continuity is handled across reorders, since a customer comparing results across time will ask you that question eventually. Ask how restocks are communicated and whether you get advance notice before a compound goes unavailable. Ask what labeling ships on the vial, and confirm that research-use-only designation is present and unambiguous — your own compliance posture depends partly on the material arriving labeled correctly. If private labeling is part of your plan, ask where the responsibility for documentation sits once your name is on the box.

Finally, ask about origin and fulfillment path. Domestic fulfillment removes customs variability from your lead time, which matters most for exactly the episodic, time-sensitive demand described above.

Compliance questions that belong with your counsel

This section is informational and is not legal advice. Whether your business may purchase, hold, relabel, or resell research-use-only compounds depends on your business structure, your professional licensure if any, and the rules of the jurisdiction you operate in — and those rules are not uniform. Rather than assume a position, bring specific questions to your attorney and your state board: How does our license class, if we hold one, interact with holding research-use-only materials? What labeling and record-keeping obligations attach to us as a reseller rather than an end user? What representations may we make in marketing, and which ones create exposure? How should purchase records and lot documentation be retained?

No supplier can answer those for you, and any supplier that offers to should be treated with suspicion. Real Peptides supplies material and documentation; your regulatory posture is yours and your counsel's to define.

What Real Peptides does differently

Real Peptides tests every batch to a seven-panel standard and publishes the results where partners and their customers can verify them independently — the certificate is retrievable by lot rather than issued on request or sold separately. Purity is reported at 99%+ by HPLC, with identity confirmation handled as its own test rather than folded into the purity claim. Orders are fulfilled from within the United States, with shipping in five to seven days, which keeps customs variability out of your lead time.

Wholesale pricing tiers are published rather than gated behind a discovery call, so you can model your costs before you speak to anyone. Access runs through a three-step Wholesale Partner Program application: submit your business details, complete verification, and receive tier pricing and account access. Real Peptides does not provide dosing, timing, preparation, or administration guidance for any compound in the catalog, because these are research-use-only materials — what it provides instead is concentration information expressed as milligrams per milliliter, and the documentation to confirm what is actually in the vial.

Where qualified buyers go next

If you are a med spa, clinic, telehealth operator, or reseller building a catalog around the growth hormone axis and you want pricing you can see and lab results you can check yourself, the Wholesale Partner Program application is the entry point. Verification is straightforward for an established business, and tier pricing is visible from the moment your account is active.

Buyers building depth in this category often review the adjacent secretagogue chemistry alongside sermorelin research — compounds such as CJC-1295 No DAC 10mg, Ipamorelin 10mg, and Tesamorelin 10mg — and the broader Growth Factor & Tissue Signaling Research and Popular Peptides collections are the fastest way to see how the category fits together before you set your opening order.